Jubilant Therapeutics Inc, A Biopharmaceutical Company, Announced Us Food And Drug Administration (Fda) Clearance Of The Investigational New Drug Application (Ind) For Jbi-802, A Novel, Oral, Potent And Selective Dual Inhibitor Of Lsd1 And Hdac6, For The Treatment Of Small Cell Lung Cancer (Sclc), Treatment-Induced Neuro-Endocrine Prostate Cancer (Nepc) And Other Mutation-Defined Neuroendocrine Tumours.The Phase 1/2A Trial Is An Open-Label, Two-Part Dose Escalation And Expansion Study Designed To Define The Safety Profile And Preliminary Activity Of Jbi-802 In Participants With Advanced Solid Tumours. The Study Population Will Include Patients With Locally Advanced Or Metastatic Solid Tumours Whose Disease Has Failed Prior Standard Therapy. Expansion Cohorts Of Participants With Sclc, Nepc, And Other Neuroendocrine-Derived Cancers Will Be Enrolled To Obtain Additional Safety And Efficacy Data.Hari S Bhartia, Chairman, Jubilant Therapeutics Said
